Download video

Dr. Bunn on Targeting HER3 in NSCLC

121 views

OncLive

4 years ago

Dr. Bunn on Targeting HER3 in NSCLC

Dr. Bunn on Targeting HER3 in NSCLC

Dr. Bunn on Targeting HER3 in NSCLC
1:10
Dr. Bunn on Targeting HER3 in NSCLC
by OncLive
Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies
58:27
Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies
by PeerView Oncology
Dr. Bunn on Treating Advanced-Stage Lung Cancer with TKIs
1:07
Dr. Bunn on Treating Advanced-Stage Lung Cancer with TKIs
by Targeted Oncology
Rational for HER3-targeting in NRG1 fusion-positive NSCLC
0:34
Rational for HER3-targeting in NRG1 fusion-positive NSCLC
by VJOncology
Are You Prepared for the New Wave of ADCs in NSCLC? Targeting HER2, HER3, TROP2, and Others
56:23
Are You Prepared for the New Wave of ADCs in NSCLC? Targeting HER2, HER3, TROP2, and Others
by PeerView Oncology
Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLC
1:10
Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLC
by OncLive
The Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC
58:30
The Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC
by PeerView Oncology
Necitumumab: Targeting EGFR with next-generation antibodies - Paul Bunn
18:00
Necitumumab: Targeting EGFR with next-generation antibodies - Paul Bunn
by Thoracic Malignancies and Head and Neck Cancer
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutate...
5:27
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutate...
by ecancer
Moving Toward Expanded Precision Treatment of HER2- or HER3-Driven Breast, GI, Lung \& Other Cancers
1:30:06
Moving Toward Expanded Precision Treatment of HER2- or HER3-Driven Breast, GI, Lung \& Other Cancers
by PeerView Oncology
Considering a Clinical Trial for Lung Cancer Treatment? What You Should Know
2:21
Considering a Clinical Trial for Lung Cancer Treatment? What You Should Know
by Patient Empowerment Network
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
27:30
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
by ReachMD
Drs. Johnson, Levy, \& Yu discuss the latest Lung Cancer updates from #WCLC21: https:\/\/bit.ly\/3gOriYo
1:02:54
Drs. Johnson, Levy, \& Yu discuss the latest Lung Cancer updates from #WCLC21: https:\/\/bit.ly\/3gOriYo
by PeerView Oncology
Dr. Pennell on the Evolution of Targeting HER2 in Lung Cancer
2:22
Dr. Pennell on the Evolution of Targeting HER2 in Lung Cancer
by OncLive
Dr. Falchook on KTN3379 in Advanced Tumors on KTN3379 in Advanced Tumors
1:24
Dr. Falchook on KTN3379 in Advanced Tumors on KTN3379 in Advanced Tumors
by OncLive
IASLC Webinar: World Conference on Lung Cancer 2020 Highlights
59:17
IASLC Webinar: World Conference on Lung Cancer 2020 Highlights
by IASLC
HER2 Targeted Therapy for Treatment of NSCLC
17:15
HER2 Targeted Therapy for Treatment of NSCLC
by OncLive
#ESMO21 Expert Video Report on targeting in HER2-positive metastatic breast and lung cancers
5:45
#ESMO21 Expert Video Report on targeting in HER2-positive metastatic breast and lung cancers
by European Society for Medical Oncology (ESMO)
Dr Bhavesh Poladia, Patritumab Deruxtecan HER3 DXd in EGFR Mutated NSCLC | CRSF
7:57
Dr Bhavesh Poladia, Patritumab Deruxtecan HER3 DXd in EGFR Mutated NSCLC | CRSF
by CRSF - Cancer Research and Statistic Foundation
Seribantumab (MM-121): Targeting HER3 in NSCLC - Art Kudla
10:54
Seribantumab (MM-121): Targeting HER3 in NSCLC - Art Kudla
by Thoracic Malignancies and Head and Neck Cancer